Get started
Author

Andrea Ghelli Luserna di Rorà

Observed names: A. Ghelli Luserna Di Rora, A. Ghelli Luserna Di Rora’, A. Ghelli Luserna di Rora’, A. Ghelli Luserna di Rorà, Andrea Ghelli Luserna Di Rora, Andrea Ghelli Luserna Di Rora`, Andrea Ghelli Luserna Di Rorà, Andrea Ghelli Luserna Di Rorà, Andrea Ghelli Luserna Di Rorá, Andrea Ghelli Luserna di Rora, Andrea Ghelli Luserna di Rorá, Di Rora`, Andrea, ghelli luserna di rora', andrea
Institution: Fondazione Pisa
ORCID: 0000-0002-9744-0533
Observed ORCID: 0000-0002-9744-0533
OpenAlex ID: A5019004022
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
2020 · Andrea Ghelli Luserna di Rorà, Claudio Cerchione, et al. · Journal of Hematology & Oncology · 340
PDF
Chromothripsis in acute myeloid leukemia: biological features and impact on survival
2018 · Maria Chiara Fontana, Giovanni Marconi, et al. · Leukemia · 112
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
2022 · Antonella Padella, Andrea Ghelli Luserna Di Rorà, et al. · Journal of Hematology & Oncology · 106
PDF
The cell cycle checkpoint inhibitors in the treatment of leukemias
2017 · A. Ghelli Luserna di Rora’, I. Iacobucci, et al. · Journal of Hematology & Oncology · 96
PDF
CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
2022 · Samantha Bruno, Andrea Ghelli Luserna di Rorà, et al. · Journal of Experimental & Clinical Cancer Research · 83
PDF
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
2015 · Enrico Derenzini, Claudio Agostinelli, et al. · Oncotarget · 61
PDF
The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
2019 · Andrea Ghelli Luserna di Rorà, Giovanni Martinelli, et al. · Journal of Hematology & Oncology · 55
PDF
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
2018 · Andrea Ghelli Luserna Di Rorà, Neil Beeharry, et al. · Journal of Hematology & Oncology · 52
PDF
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
2021 · Massimo Martino, Filippo Antonio Canale, et al. · Cancers · 41
PDF
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
2016 · Andrea Ghelli Luserna Di Rorà, Ilaria Iacobucci, et al. · Oncotarget · 41
PDF
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations
2021 · Giorgia Simonetti, Carlo Mengucci, et al. · Leukemia · 40
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
2016 · Stefania Trino, Ilaria Iacobucci, et al. · Oncotarget · 37
Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients
2018 · Serena De Matteis, Chiara Molinari, et al. · Journal of Translational Medicine · 33
PDF
The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias
2015 · Maria Vittoria Verga Falzacappa, Chiara Ronchini, et al. · Molecular Cancer Therapeutics · 31
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia
2015 · Ilaria Iacobucci, Andrea Ghelli Luserna Di Rorà, et al. · Journal of Hematology & Oncology · 30
PDF
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
2021 · Andrea Ghelli Luserna Di Rorà, Martina Ghetti, et al. · Cell Biology and Toxicology · 29
PDF
Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
2019 · Andrea Ghelli Luserna Di Rorà, Matteo Bocconcelli, et al. · Cancers · 29
PDF
Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions
2015 · Neil Beeharry, Andrea Ghelli Luserna Di Rora, et al. · Cancer Biology & Therapy · 28
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
2021 · Daniele Caracciolo, Caterina Riillo, et al. · Journal for ImmunoTherapy of Cancer · 26
PDF
Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia
2019 · Antonella Padella, Giorgia Simonetti, et al. · Cancers · 24
Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents
2021 · Giorgia Simonetti, Carla Boga, et al. · Molecules · 23
PDF
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
2021 · Michele Gottardi, Giorgia Simonetti, et al. · Cancers · 20
PDF
Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
2023 · Anna Ferrari, Delia Cangini, et al. · Frontiers in Cell and Developmental Biology · 18
PDF
Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon
2023 · Andrea Ghelli Luserna di Rorà, Mouna Jandoubi, et al. · Molecules · 18
PDF
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future
2020 · Michele Gottardi, Alessandra Sperotto, et al. · Minerva Medica · 18
Works count: 110
Citation count: 1,508
H-index: 21
I10-index: 28
Year
Topic
Type